Imatinib-induced irreversible interstitial lung disease: A case report

RATIONALE: Imatinib mesylate (imatinib) is a classic tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Although it is well tolerated by most patients and helps in the achievement of complete remission, a few rare imatinib-associated adverse effects such as pulmonary interstitial fibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ping, Huang, Jingfeng, Jin, Fangfang, Pan, Jiaohai, Ouyang, Guifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407980/
https://www.ncbi.nlm.nih.gov/pubmed/30813141
http://dx.doi.org/10.1097/MD.0000000000014402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407980/
https://www.ncbi.nlm.nih.gov/pubmed/30813141
http://dx.doi.org/10.1097/MD.0000000000014402

Ejemplares similares